A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer.

Trial Profile

A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Bortezomib; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2011 Planned end date changed from Mar 2009 to Oct 2009 as reported by ClinicalTrials.gov.
    • 08 Aug 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 22 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top